Summary: The global warming effect may have a major influence on the necessity to reduce the generation of greenhouse gases in medicine. This could influence the treatment of asthma and COPD. We should introduce the utilization of low carbon footprint inhalers and propellants instead of the current ones. In the spectra of dry powder inhalers available for asthma treatment, the Spiromax seems to be the one mostly preferred by patients. Interestingly, patientsʼ opinion is supported by several clinical research trials. Last but not least, this inhaler is characterized by a very low carbon foot print. Therefore, Spi-romax and some other dry powder inhalers should be utilized in asthma and COPD treatment also due to their low carbon footprints.